Shelter Ins Retirement Plan Sells 4,000 Shares of Abbott Laboratories (NYSE:ABT)

Shelter Ins Retirement Plan decreased its stake in shares of Abbott Laboratories (NYSE:ABT) by 5.0% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 75,700 shares of the healthcare product maker’s stock after selling 4,000 shares during the period. Abbott Laboratories accounts for approximately 1.9% of Shelter Ins Retirement Plan’s holdings, making the stock its 27th biggest holding. Shelter Ins Retirement Plan’s holdings in Abbott Laboratories were worth $4,039,000 as of its most recent SEC filing.

A number of other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Abbott Laboratories by 2.6% during the 2nd quarter. Vanguard Group Inc. now owns 129,786,955 shares of the healthcare product maker’s stock valued at $6,308,944,000 after purchasing an additional 3,241,063 shares during the period. Capital Research Global Investors lifted its position in Abbott Laboratories by 45.7% during the 2nd quarter. Capital Research Global Investors now owns 47,589,663 shares of the healthcare product maker’s stock valued at $2,313,334,000 after purchasing an additional 14,918,038 shares during the period. Northern Trust Corp lifted its position in Abbott Laboratories by 3.1% during the 2nd quarter. Northern Trust Corp now owns 26,865,706 shares of the healthcare product maker’s stock valued at $1,305,942,000 after purchasing an additional 809,732 shares during the period. Dimensional Fund Advisors LP lifted its position in Abbott Laboratories by 28.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 11,722,088 shares of the healthcare product maker’s stock valued at $569,830,000 after purchasing an additional 2,606,404 shares during the period. Finally, Alliancebernstein L.P. lifted its position in Abbott Laboratories by 7.7% during the 2nd quarter. Alliancebernstein L.P. now owns 11,607,121 shares of the healthcare product maker’s stock valued at $564,222,000 after purchasing an additional 830,610 shares during the period. Institutional investors own 71.19% of the company’s stock.

In other Abbott Laboratories news, Chairman Miles D. White sold 276,886 shares of the firm’s stock in a transaction on Wednesday, December 6th. The stock was sold at an average price of $54.41, for a total transaction of $15,065,367.26. Following the completion of the sale, the chairman now owns 3,677,913 shares of the company’s stock, valued at approximately $200,115,246.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of the firm’s stock in a transaction on Monday, October 23rd. The shares were sold at an average price of $56.21, for a total value of $5,430,054.63. Following the sale, the executive vice president now directly owns 142,082 shares of the company’s stock, valued at approximately $7,986,429.22. The disclosure for this sale can be found here. In the last three months, insiders sold 501,172 shares of company stock valued at $27,533,150. 0.76% of the stock is currently owned by insiders.

A number of research firms have issued reports on ABT. Royal Bank of Canada restated a “buy” rating and set a $65.00 target price on shares of Abbott Laboratories in a research report on Tuesday, January 9th. Barclays reaffirmed a “buy” rating and issued a $66.00 price target on shares of Abbott Laboratories in a research note on Monday, January 8th. Zacks Investment Research cut Abbott Laboratories from a “buy” rating to a “hold” rating in a research note on Wednesday, January 3rd. Evercore ISI began coverage on Abbott Laboratories in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $64.00 price target for the company. Finally, JPMorgan Chase & Co. raised Abbott Laboratories from a “neutral” rating to an “overweight” rating and set a $60.00 price target for the company in a research note on Tuesday, January 2nd. Six investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. Abbott Laboratories currently has a consensus rating of “Buy” and an average price target of $60.24.

Shares of Abbott Laboratories (NYSE ABT) traded up $0.25 on Tuesday, hitting $59.09. 491,467 shares of the stock traded hands, compared to its average volume of 6,184,067. The company has a market cap of $102,420.00, a PE ratio of 48.83, a P/E/G ratio of 1.87 and a beta of 1.55. Abbott Laboratories has a one year low of $39.25 and a one year high of $59.60. The company has a quick ratio of 2.26, a current ratio of 2.69 and a debt-to-equity ratio of 0.72.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.01. The company had revenue of $6.83 billion during the quarter, compared to analysts’ expectations of $6.72 billion. Abbott Laboratories had a net margin of 8.37% and a return on equity of 13.98%. The business’s quarterly revenue was up 28.8% on a year-over-year basis. During the same period last year, the business earned $0.59 EPS. equities research analysts forecast that Abbott Laboratories will post 2.5 EPS for the current year.

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, February 15th. Stockholders of record on Friday, January 12th will be issued a $0.28 dividend. This represents a $1.12 annualized dividend and a dividend yield of 1.90%. The ex-dividend date is Thursday, January 11th. This is an increase from Abbott Laboratories’s previous quarterly dividend of $0.27. Abbott Laboratories’s dividend payout ratio is presently 92.56%.

ILLEGAL ACTIVITY NOTICE: “Shelter Ins Retirement Plan Sells 4,000 Shares of Abbott Laboratories (NYSE:ABT)” was reported by BBNS and is owned by of BBNS. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://baseballnewssource.com/markets/abbott-laboratories-abt-shares-sold-by-shelter-ins-retirement-plan/1820529.html.

Abbott Laboratories Company Profile

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Rumor: Milwaukee Brewers Offer Yu Darvish Contract
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Report: 20-Second Clock and Limit on Mound Visits Rejected by MLBPA
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Christian Yelich’s Agent Says Relationship with Marlins is Broken
Houston Astros Add Starter to Rotation
Houston Astros Add Starter to Rotation
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Sources: Mets Bringing Back Jay Bruce with Three-Year Deal
Justin Morneau Former Star With Twins and AL MVP Retires
Justin Morneau Former Star With Twins and AL MVP Retires


Leave a Reply

 
© 2006-2018 BBNS.